Recursion Pharmaceuticals, Inc.(RXRX)NASDAQ
Stock Overview & Analysis
Recursion Pharmaceuticals, Inc. (RXRX) quick overview 2026-02-20
- The stock is currently trading at $3.42, experiencing a short-term pullback within a declining trend—trading below its 50-day average while below the 200-day.
- Analysts appear optimistic, with a 1-year price target of $7.00 (104.7% upside).
- Volatility is elevated (64.27% annualized), implying wide price swings.
- The fundamental story is nuanced: solid revenue growth (-80.20% YoY) alongside significant competitive pressures.
Here's What You Need to Know Right Now
Concise, actionable context
Recursion Pharmaceuticals, Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $1.26B
P/E Ratio
Forward P/E: -3.14
Revenue Growth
Year over Year
Analyst Target
+104.7% upside potential
Key Investor Questions
Clarity over jargon
- Technicals say: Neutral (RSI 34.02)
- Fundamentals say: Challenging (declining revenue trends)
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
- $82.37M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
Trading Range
Over the past year, the stock traded between $3.44 and $12.36—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility
With 64.27% annualized volatility and β=0.95, the stock exhibits moderate correlation to market moves—suitable for investors comfortable with active risk management.
Ownership Snapshot
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment
Latest News
Recent headlines and coverage
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Ark Invest added to three positions that are well below last year's highs.
Recursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $3.42, marking a -8.06% move from the previous day.
Cathie Wood Pours $24 Million to This AI Software Stock
ARK Loads Up on Figma After Earnings. DraftKings and Pinterest Get Trimmed
Travere Therapeutics (TVTX) Matches Q4 Earnings Estimates
Travere (TVTX) delivered earnings and revenue surprises of +16.73% and -8.97%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Nvidia Dumped Recursion Pharmaceuticals Stock. Should You?
Nvidia sold its position in Recursion Pharmaceuticals, while others keep a measured outlook. Does this divergence signal risk or opportunity?
Nvidia Dumped It, Cathie Wood Snapped It Up. This Pharma Stock Is Splitting Wall Street.
Nvidia sold its entire stake in a drug-discovery company at the end of last year. ARK Invest is buying the stock.
NVIDIA’s 13F Bombshell: A New AI Power Trio Emerges
NVIDIA did anything but stand pat with its investments during Q4 2025. See how the company turned over its holdings in the quarter.
Nvidia Dumped It, Cathie Wood Snapped It Up. This Pharma Stock Is Splitting Wall Street.
Nvidia sold its entire stake in a drug-discovery company at the end of last year. ARK Invest is buying the stock.
Applied Digital (APLD) Loses 4.9% as Nvidia Disposes of Shares
We recently published 10 Losing Stocks in an Otherwise Optimistic Market. Applied Digital Corp. (NASDAQ:APLD) was one of the worst performers on Wednesday. Applied Digital extended its losing streak to a sixth straight day on Wednesday, dropping 4.92 percent to close at $31.91 apiece, as investor sentiment was further dragged by news that Nvidia Corp. […]
Major Backers Exit As Recursion Deepens Commitment To REC-102 Pipeline
Major investors Nvidia and Novo Holdings A/S have fully exited their positions in Recursion Pharmaceuticals (NasdaqGS:RXRX), signaling a shift in institutional backing. Recursion has acquired full ownership of its joint venture for REC-102, consolidating control over this clinical asset. The company’s shares most recently closed at $3.53, with a 1 year return showing a 67.5% decline and a 30 day return showing a 24.4% decline. For a pre commercial stage biotech like Recursion...
Frequently Asked Questions
Common investor questions about Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. (RXRX) is currently trading at $3.42. The RSI (14-day) is at 34.0, indicating neutral territory. Wall Street analysts have a consensus "Hold" recommendation. The mean analyst price target of $7.00 implies 104.7% upside from current levels. Volatility is high at 64.3% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Recursion Pharmaceuticals, Inc. (RXRX): The trailing P/E ratio is not available (the company may not be profitable). The forward P/E is -3.14. Price-to-Book is 1.72. Price-to-Sales is 43.73. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 7 analysts covering RXRX, the consensus price target is $7.00. This represents a 104.7% upside from the current price of $3.42. The range spans from a low target of $3.00 to a high target of $11.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "Hold". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Recursion Pharmaceuticals, Inc. (RXRX) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Recursion Pharmaceuticals, Inc. (RXRX) investors include: 1. High volatility (64.3% annualized)—the stock can experience significant daily price swings. 2. The company is not currently profitable on a trailing basis, which creates earnings uncertainty. 3. Declining revenue (-80.2% YoY), indicating potential business headwinds. 4. Elevated short interest (33.7% of float) suggests significant bearish sentiment. 5. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 6. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Recursion Pharmaceuticals, Inc.'s (RXRX) current debt and financial health profile: Total debt stands at $82.37M. The debt-to-equity ratio is 7.87, which is conservative and indicates a strong balance sheet with low leverage. The current ratio is 4.60, indicating strong short-term liquidity. The quick ratio is 4.39. The company holds $659.84M in cash and equivalents. Free cash flow is negative at $-227,066,496, which could limit the company's ability to manage debt obligations.